News & Updates
Filter by Specialty:
Long-term TAF tied to high viral suppression in CHB
Patients with chronic hepatitis B (CHB) who has undergone long-term treatment with tenofovir alafenamide (TAF) achieve high rates of viral suppression comparable to those of tenofovir disoproxil fumarate (TDF; or TDF switched to TAF) with favourable renal and bone safety, results of a study have shown.
Long-term TAF tied to high viral suppression in CHB
27 Mar 2024
Deuruxolitinib helps restore crowning glory in alopecia areata
Pooled analyses of the phase III THRIVEAA1 and THRIVE-AA2 trials underpin the potential of the selective oral JAK* 1/2 inhibitor deuruxolitinib to effectively and safely reverse hair loss in adults with moderate-to-severe alopecia areata (AA).
Deuruxolitinib helps restore crowning glory in alopecia areata
25 Mar 2024
Lebrikizumab plus TCS improves outcomes in moderate-to-severe AD
Treatment with lebrikizumab in combination with topical corticosteroids (TCS), compared with TCS alone, results in early and sustained improvements in patient-reported outcomes (PROs) among individuals with moderate-to-severe atopic dermatitis (AD), as shown in a Japan study.
